Intra-Cellular Therapies Inc., of New York, said it has started an underwritten public offering of $150 million of shares of its common stock and will grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering. J. P. Morgan Securities LLC and Leerink Partners LLC are acting as joint book-running managers for the offering.